Product design with recycled plastic: material study, impact measurement and application proposal within the framework of the project PlasticPLA

El present TFE es duu a terme en el marc del projecte PlasticPLA, una iniciativa amb l’objectiu de dissenyar, desenvolupar i implementar un procés industrial per a recuperar grans quantitats de residus plàstics a Barcelona, en forma de panells. Dins del projecte PlasticPLA, la finalitat del TFE és contribuir al desenvolupament de la iniciativa per tal d’incrementar-ne la viabilitat i robustesa. El treball se centra en tres àrees: Primer, la creació de coneixement sobre les propietats i aplicacions del material així com els potencials competidors. Segon, la mesura de l’impacte de la iniciativa en les dimensions ambiental, social i econòmica. Finalment, el disseny i desenvolupament d’un producte fet íntegrament amb panells PlasticPLA, com a mostra d’una de les seves possibles aplicacions. A partir del treball realitzat es conclou que els panels PlasticPLA són apropiats per a disseny interior domèstic i comercial i per a disseny de mobiliari. L’existència d’iniciatives similars a Espanya és residual, fet que unit amb el creixent desenvolupament d’iniciatives que fabriquen panells reciclats a nivell europeu, assenyala una oportunitat per a implementar el projecte PlasticPLA al mercat espanyol. Pel que fa a l’impacte, de forma general, es considera positiu. Ambientalment, l’ús dels panells PlasticPLA té un impacte inferior al de la majoria dels materials amb què ha estat comparat. L’impacte social del projecte rep la qualificació més elevada, contribució a solucions per als grups d’interès involucrats. Finalment, el projecte resulta econòmicament viable i genera una valorització econòmica dels residus plàstics d’un 70%. El resultat de l’exercici de disseny és una taula auxiliar que implementa estratègies d’eco-disseny que mostra una de les moltes possibles maneres de tancar el cicle iniciat amb la fabricació de panells a partir de plàstic reciclat.The present thesis is conducted under the umbrella of the project PlasticPLA, an initiative to design, develop and implement an industrial process to upgrade large amount of plastic waste in Barcelona by producing recycled plastic panels. Within the PlasticPLA project framework, this thesis aims to develop further the initiative to improve its viability and robustness by focusing in three areas. First, building knowledge around the material properties and applications as well as identifying potential competitors. Second, measuring the project impact according to the environmental, social and economic dimensions. Third, developing a product manufactured entirely with PlasticPLA panels, as an example of a potential application. From the present thesis it is concluded that PlasticPLA panels are suitable for furniture design and domestic and retail & hospitality interior design applications. The presence of similar initiatives in Spain is low. This fact, together with the increasing number of organizations manufacturing panels with recycled materials globally, points out a market opportunity in Spain to implement the project PlasticPLA. Regarding the project impact, it is altogether considered positive. Regarding environmental impact, panels generate a lower impact than most of the materials they are compared with. Regarding social impact, the project obtains the highest score, contribute to solutions for the involved stakeholders. Finally, the project is economically viable. Moreover, it leads to an economic revalorization of plastic waste around 70%. The result derived from the design exercise is an auxiliary table which implements eco-design strategies, showing one of many possible ways to close the loop, originated with the manufacture of recycled plastic panels

Comparison between Eurocodes and UK standards (BDs) for structural assessment. The Case Study of Ashworth Viaduct

Within the scope of safety and preservation of historical memory of existing bridges, maintenance of bridges has become one of the most important issues to the economy, society and public interest. To achieve this objective, an efficient management of bridges is needed, being implied in the process, periodic inspections and structural assessments, followed by repair, rehabilitation or strengthening, if necessary. However, drastic actions, such as demolition and/or substitution have to be considered when the structure does not accomplish the minimum requirements of the new standards or it is not economically viable for any other intervention. This work concentrates on an essential aspect within the process of maintenance, which is the structural assessment of existing bridges. Therefore, an approach regarding this subject is carried out using two different methods of assessment, one based in the Eurocodes and the other one guided by the UK standards for structural assessments, having as the main aim the comparison of these two standards. To better understand the evolution of bridges in the United Kingdom, a historical approach is developed as first contact, highlighting the beginning of great constructions in history, using as material construction, steel, concrete and steel-concrete composite. It is known that bridges have been through great changes in traffic load over time affecting thus, their maintenance and the need for structural assessment. On one side’ this came to encourage the UK in creating unique standards made specifically for structural assessment (BDs) of bridges. On the other side, the Eurocodes, despite having been created specifically for design of new bridges, are adapted to the assessment of existing bridges, being used in many other countries around Europe. Throughout this work, the main differences between these two standards, mentioned above, are described taking into account the actions applied on bridges, the used partial safety factors, the properties and capacity of construction materials and the effects of the actions observed in the structural members. To support this comparison, it is also introduced a composite viaduct existing in the UK, where it is possible to take the distinct results from the different models of forces acting on the structure. In conclusion, an analysis of the two results is carried out in order to register the difference between both codes and discuss main features for future structural assessment works. BDs has been registered to be more conservative than Eurocodes although the results between them do not show a high discrepancy

Pharmacovigilance of calcineurin inhibitors in pediatric kidney and liver transplantation

Objetivo: Desarrollar un programa de farmacovigilancia de pacientes pediátricos trasplantados hepáticos y renales centrado en inmunosupresores calcineurínicos del Hospital de Pediatría JP Garrahan de Argentina. Métodos: Se evaluaron las reacciones adversas a medicamentos (RAM) de los pacientes pediátricos trasplantados renales y hepáticos de nuestro hospital tratados con inhibidores de calcineurina (ciclosporina y tacrolimus) por revisión retrospectiva de historias clínicas de pacientes trasplantados en 2010-2011, y análisis prospectivo por farmacovigilancia activa de trasplantados fuera de dicho período, cuyas complicaciones se hayan presentado en los ateneos semanales del Servicio de Trasplante desde marzo de 2011. Las RAM se notificaron a la autoridad sanitaria nacional. Resultados: Se analizaron un total de 59 pacientes, 28 trasplantados renales y 31 hepáticos. Se notificaron, en ambos trasplantes, 60 RAM a ciclosporina destacándose (número de casos) hipertensión arterial (19) y nefrotoxicidad (6). Asimismo, se registraron 46 RAM a tacrolimus, incluyendo hipomagnesemia (25), hipertensión (7) y nefrotoxicidad (5). El 95% y 96% de los eventos adversos a ciclosporina y a tacrolimus, respectivamente, han sido agrupados como probables o definitivos. El 70% y 98% de los eventos adversos a ciclosporina y a tacrolimus respectivamente, han sido de severidad moderada o grave. Conclusiones: Este es el primer proyecto en América Latina que propone y desarrolla el estudio cuali-cuantitativo intensivo de RAM a inhibidores de calcineurina en trasplante pediátrico renal y hepático. Es necesario estimular la notificación espontánea así como continuar el seguimiento de RAM a mediano y largo plazo para mejorar la calidad de vida del paciente trasplantado.Aim: To develop a pharmacovigilance program of calcineurin inhibitors used in pediatric renal and liver transplant patients at Hospital de Pediatría JP Garrahan, Argentina. Methods: Adverse drug reactions (ADRs) of pediatric patients with kidney and liver transplantation treated with calcineurin inhibitors (cyclosporine and tacrolimus) were evaluated by retrospective review of medical records of patients transplanted between 2010 and 2011. In addition, we carried out active pharmacovigilance since March, 2011. ADRs were reported to the National Health Authority. Results: A total of 59 patients, 28 kidney transplant and 31 liver tarnsplant patients were analyzed. In both transplants, 60 ADRs to cyclosporine were reported including (number of cases), hypertension (19) and nephrotoxicity (6). In addition, 46 ADRs to tacrolimus were registered as hypomagnesemia (25), hypertension (7) and nephrotoxicity (5). A total of 95% and 96% of the adverse events to cyclosporine and tacrolimus, respectively, were defined as probable or definitive. Lastly, 70% and 98% of the events to cyclosporine and tacrolimus respectively, have been moderately severe or severe. Conclusions: This is the first study in Latin America that developed an intensive qualitative and quantitative analysis of the ADRs to calcineruin inhibitors in pediatric kidney and liver transplant patients. Spontaneous reporting should be motivated as well as monitoring ADRs should continue in the medium and long term for improving patient's quality of life.Fil: Riva, Natalia. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Caceres Guido, Paulo Arturo. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Rousseau, Marcela. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Dip, Marcelo. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Monteverde, Marta. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Imventarza, Oscar. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Mato, Gabriel. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Schaiquevich, Paula Susana. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin

Governance Review Commission General Rationale Rev 2

Bacterial infectious diseases produced by Vibrio are the main cause of economic losses in aquaculture. During recent years it has been shown that the expression of virulence genes in some Vibrio species is controlled by a population-density dependent gene-expression mechanism known as quorum sensing (QS), which is mediated by the diffusion of signal molecules such as N-acylhomoserine lactones (AHLs). QS disruption, especially the enzymatic degradation of signalling molecules, known as quorum quenching (QQ), is one of the novel therapeutic strategies for the treatment of bacterial infections. In this study, we present the detection of AHLs in 34 marine Vibrionaceae strains. Three aquaculture-related pathogenic Vibrio strains, V. mediterranei VibC-Oc-097, V. owensii VibC-Oc-106 and V. coralliilyticus VibC-Oc-193 were selected for further studies based on their virulence and high production of AHLs. This is the first report where the signal molecules have been characterized in these emerging marine pathogens and correlated to the expression of virulence factors. Moreover, the results of AHL inactivation in the three selected strains have been confirmed in vivo against brine shrimps (Artemia salina) and Manila clams (Venerupis philippinarum). This research contributes to the development of future therapies based on AHL disruption, the most promising alternatives for fighting infectious diseases in aquaculture.This research was supported in part by grants from the Ministerio de Economía y Competitividad (Spain) (http://www.mineco.gob. es/portal/site/mineco/idi) (AGL2012-39274-C02- 02; AGL2015-68806-R; AGL2015-63740-C2-2-R). José Carlos Reina is supported by a FPU fellowship rom the Ministerio de Educación, Cultura y Deporte (Spain) (https://www.mecd.gob.es/ portada-mecd/) (FPU15-01717) and a Initiation to Research fellowship for Master Students (2016) from the University of Granada (Spain

The Siderophore Piscibactin Is a Relevant Virulence Factor for Vibrio anguillarum Favored at Low Temperatures

Vibrio anguillarum causes vibriosis, a hemorrhagic septicaemia that affects many cultured marine fish species worldwide. Two catechol siderophores, vanchrobactin and anguibactin, were previously identified in this bacterium. While vanchrobactin is a chromosomally encoded system widespread in all pathogenic and environmental strains, anguibactin is a plasmid-encoded system restricted to serotype O1 strains. In this work, we have characterized, from a serotype O2 strain producing vanchrobactin, a novel genomic island containing a cluster of genes that would encode the synthesis of piscibactin, a siderophore firstly described in the fish pathogen Photobacterium damselae subsp. piscicida. The chemical characterization of this siderophore confirmed that some strains of V. anguillarum produce piscibactin. An in silico analysis of the available genomes showed that this genomic island is present in many of the highly pathogenic V. anguillarum strains lacking the anguibactin system. The construction of single and double biosynthetic mutants for vanchrobactin and piscibactin allowed us to study the contribution of each siderophore to iron uptake, cell fitness, and virulence. Although both siderophores are simultaneously produced, piscibactin constitute a key virulence factor to infect fish, while vanchrobactin seems to have a secondary role in virulence. In addition, a transcriptional analysis of the gene cluster encoding piscibactin in V. anguillarum showed that synthesis of this siderophore is favored at low temperatures, being the transcriptional activity of the biosynthetic genes three-times higher at 18°C than at 25°C. We also show that iron levels and temperature contribute to balance the synthesis of both siderophoresThis work was supported by grants AGL2015-63740-C2-1-R and AGL2015-63740-C2-2-R (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, and co-funded by the FEDER Programme from the European Union. The support of Xunta de Galicia (Spain) with grant GRC-2014/007 is also acknowledgedS

Antimicrobial Diterpene Alkaloids from an Agelas citrina Sponge Collected in the Yucatán Peninsula

[Abstract] Three new diterpene alkaloids, (+)-8-epiagelasine T (1), (+)-10-epiagelasine B (2), and (+)-12-hydroxyagelasidine C (3), along with three known compounds, (+)-ent-agelasine F (4), (+)-agelasine B (5), and (+)-agelasidine C (6), were isolated from the sponge Agelas citrina, collected on the coasts of the Yucatán Peninsula (Mexico). Their chemical structures were elucidated by 1D and 2D NMR spectroscopy, HRESIMS techniques, and a comparison with literature data. Although the synthesis of (+)-ent-agelasine F (4) has been previously reported, this is the first time that it was isolated as a natural product. The evaluation of the antimicrobial activity against the Gram-positive pathogens Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis showed that all of them were active, with (+)-10-epiagelasine B (2) being the most active compound with an MIC in the range of 1–8 µg/mL. On the other hand, the Gram-negative pathogenes Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae were also evaluated, and only (+)-agelasine B (5) showed a moderate antibacterial activity with a MIC value of 16 μg/mL.This work was supported by grants RTI2018-093634-B-C22 from the State Agency for Research (AEI) of Spain, cofunded by the FEDER Programme from the European Union (MCIN/AEI/10.13039/501100011033/FEDER) and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). This work was supported by Projects PI17/01482 and PI20/01212 awarded to AB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2017–2020 and funded by the ISCIII—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas). The study was also funded by project IN607D 2021/12 (GAIN-Agencia Gallega de Innovación—Consellería de Economía, Emprego e Industria) awarded to AB. The study was also funded by projects GRC2018/039 from Xunta de Galicia. Dawrin Pech-Puch received his postdoctoral fellowship from the National Council of Science and Technology (CONACYT) of Mexico. This work was supported by the Max Planck Society and the DFG (Gr1211/19-1)/CAPES 418729698 projectXunta de Galicia; IN607D 2021/12Xunta de Galicia; GRC2018/039Deutsche Forschungsgemeinschaft = German Research Foundation; Gr1211/19-1Brasil. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES); 41872969

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced 651 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with 651 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not 655. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin

Near-adult height in male kidney transplant recipients started on growth hormone treatment in late puberty

Background: Growth retardation and its impact on adult height is considered to be one of the most common complications in patients with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (rhGH) has been effective in improving growth in kidney transplantation (KTx) patients, but little data are available on adult height in patients who began rhGh treatment in late puberty. Methods: Near-adult height was evaluated in 13 KTx patients treated with rhGH [growth hormone group (GHGr); dose 9.33 mg/m2 per week] for a period of at least 18 months. At initiation of rhGH treatment, testicular volume was >8 ml and serum testosterone was >1 ng/ml compared with the control group (CGr) of ten KTx patients who did not receive rHGH. All subjects were of similar chronological age and bone age and had similar creatinine clearance (CrCl) levels, cumulative corticoid dose, height standard deviation score (SDS), target height SDS, and target height:initial height at the beginning of the study. Results: Near-adult height was significantly greater in the GHGr than in the CGr (−1.8 ± 0.8 vs. −2.9 ± 1.1; p = 0.018). The difference between initial height and near-adult height in the GHGr revealed a significant height gain (initial height −3.1 ± 1.1; near-adult height −1.8 ± 0.8 SDS, respectively; delta 1.2 ± 0.3; p = 0.021). The CrCl level was not significantly different between the GHGr and CGr at either at study initiation or when attaining near-adult height (p = 0.74 and p = 0.23, respectively). Conclusions: Treatment with rhGH was effective in improving adult height in KTx patients who began treatment in late puberty, without any effect on renal function.Fil: Gil, Silvia. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Aziz, Mariana. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Adragna, Marta. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Monteverde, Marta. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; ArgentinaFil: Belgorosky, Alicia. Gobierno de la Ciudad de Buenos Aires. Hospital de Pediatría "Juan P. Garrahan"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin